About Us

“Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realise the promise of future therapeutics.”

-Kiran Mazumdar-Shaw, Chairman & Managing Director

Biocon, India’s largest biotech company is focused on delivering affordable innovation.

It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India’s cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.

Biocon’s key innovations include world’s first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India’s first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.

Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets.

Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries.

As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market.

Leveraging India’s globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene.

Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle.

With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine.

Awards for Biocon in 2013

Biocon makes it to the Top Ten Most Admired Companies in the Pharma & Healthcare Sector, Fortune India Magazine, July

Biocon wins ABLE 10th Anniversary Award for Outstanding Contribution to Biopharmaceuticals for the decade, 2002-2012

Biocon wins Best Design and Innovation Exhibitor Award at Bangalore India Bio

Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the Science Magazine

Products and Services:

ALZUMAb™ is the World’s first novel anti-CD6 antibody developed by Biocon to address a large unmet need for the treatment of Psoriasis in India.

– Excellent safety and efficacy profile with very low opportunistic infection rates and longer remission period

– Offers a new treatment option for Psoriasis with a less aggressive dosing regimen and a longer treatment free period, ensuring better patient compliance and convenience

– Is an innovative affordable treatment option with a promise to offer a better quality of life for the patient

– Will provide an effective biologic treatment solution to 1-2% of Indian population suffering from Psoriasis

– ALZUMAb™ (Itolizumab) has demonstrated preclinical and/clinical evidence in treating other autoimmune diseases like rheumatoid arthritis, psoriatic arthritis and multiple sclerosis.

– Biocon is committed to offering this novel anti-CD6 biologic from India to patients across the globe

Inflammatory autoimmune diseases like Psoriasis, Rheumatoid Arthritis and Multiple Sclerosis require therapeutic intervention to modulate the immune system and alleviate disease symptoms. Autoimmune diseases are chronic in nature and patients require life long treatment. T-Cells found in the immune system which cause these diseases are a natural target for immunomodulation.

Itolizumab is the world’s ‘first-in-class’ humanized anti-CD6 monoclonal antibody (MAb) that has a unique mechanism of action (MOA) targeting the CD6 pathway. CD6 is a pan T-Cell marker involved in co-stimulation, adhesion and maturation of T-Cells, which have been found to play a leading role in autoimmune diseases. Itolizumab, by binding to CD6, down regulates T-Cell activation, causes reduction in synthesis of proinflammatory cytokines and possibly plays an important role by reducing T-Cell infiltration at sites of inflammation.

Emerging data shows that in addition to Th1, Th17 cells play a critical role in autoimmune diseases. Itolizumab is the world’s first anti-CD6 biologic addressing the Th17 pathway that has completed its ‘Lab to Market’ journey, making Biocon a front-runner in the race to develop biologics targeting the Th17 pathway.

Unlike other biologics like cytokine inhibitors which act downstream in the pro-inflammatory cascade, Itolizumab acts upstream inhibiting the formation of cytokines, resulting in lower infection rates and longer remission periods.

In addition to the Phase 3 TREAT-PLAQ study, two positive Phase 2a dose finding studies have been conducted one each in rheumatoid arthritis and psoriasis. A total of over 300 patients have been treated with Itolizumab, of these, about 100 patients have received the drug for 52 weeks with encouraging safety and tolerability profile. Itolizumab was approved by Drugs Controller General of India for treatment of Psoriasis in India in 2013.

Biocon has launched Itolizumab as ALZUMAb™for the treatment of psoriasis in India. It is the Second Novel Biologic from Biocon to be introduced for Indian patients.